Merck halts development of nemtabrutinib after review covering 3 Phase 3 trials
Key Facts
Merck announced on 17 November 2026 that it was halting clinical development of nemtabrutinib, also known as MK-1026, after reviewing data from the BELLWAVE program for blood cancers. The company said an independent data monitoring committee concluded that the benefits may not outweigh the risks in the BELLWAVE-011 study, and Merck confirmed the halt after reviewing the data as a whole. The decision covers 3 Phase 3 trials: BELLWAVE-011, BELLWAVE-008 and BELLWAVE-010. The drug was an experimental oral BTK inhibitor being studied for chronic lymphocytic leukemia, small lymphocytic lymphoma and other blood cancers. Merck shares closed at $143.37 in the 17 November session, according to EL7 data.
BELLWAVE-011 targets previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Merck launched the study in 2023, with plans to enroll 1,200 patients, while the planned primary analysis was scheduled for 2032. Halting it ends a clinical program that had been expected to run for several more years, alongside the halt of the other two studies in the program. Merck did not announce final analysis results or provide further details on the balance of benefits and risks in its statement. The company said analysis of the trial data is ongoing and that the results will be shared with the scientific community.
The move also affects study participants. Merck said it is working to notify trial investigators of the decision. It advised patients to speak with their study team and doctor about next steps and the treatment options available to them. The company did not specify when it would publish the results of the ongoing analysis. It also gave no specific arrangements for continued care or transition to other treatment options, referring participants to their medical teams. Merck said sharing the results with the scientific community would be the next step after the analyses are complete.
The program traces its origins to Merck’s acquisition of ArQule, announced on 9 December 2019. Merck offered $20 in cash per share, valuing the equity at approximately $2.7 billion. ArQule’s lead candidate at the time was ARQ 531, which was in a Phase 2 dose-expansion study for B-cell malignancies. Merck said when announcing the deal that the asset targets both native BTK and the C481S mutation associated with resistance to other inhibitors in the class. It also said early data showed a manageable safety profile and preliminary signs of antitumor activity in patients with relapsed or refractory chronic lymphocytic leukemia and Richter transformation.
The background of the early trials offers some context on the safety considerations that accompanied the drug’s development, but does not in itself explain the decision to halt the program. In a study published in 2024, treatment-emergent adverse events of Grade 3 or higher occurred in 89% of treated patients. Neutropenia was the most prominent of those events, recorded in 23.4% of patients. Merck’s current decision was based on the data monitoring committee’s review of BELLWAVE-011, followed by the company’s review of the data as a whole. The trials are now awaiting completion of their data analyses, with Merck saying it will share the results with the scientific community.
BELLWAVE-010 tested adding nemtabrutinib to venetoclax against a venetoclax and rituximab combination in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ClinicalTrials.gov estimated the study’s enrollment at 735 participants, with an estimated completion date of 2035 before the halt was announced. Ending the study closes a program that had been planned to continue until that date, while Merck’s move also covers BELLWAVE-008 and BELLWAVE-011. The company is continuing to analyze data from the three trials, according to its statement. Merck did not specify when the results would be made available or provide details about them.